Collegium Pharmaceutical, Inc. Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent
Collegium Pharmaceutical, Inc. (COLL) reported Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent of $219.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent · last filed 2026-08-06
- Collegium Pharmaceutical, Inc. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2026-06-30 was $219.00K, a 128.13% increase year-over-year.
- Collegium Pharmaceutical, Inc. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2026-03-31 was -$538.00K, a 389.25% decline year-over-year.
- Collegium Pharmaceutical, Inc. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2025-12-31 was $27.00K.
- Collegium Pharmaceutical, Inc. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2025-09-30 was -$45.00K, a 107.83% decline year-over-year.
- Collegium Pharmaceutical, Inc. other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2025 was $264.00K, a 543.90% increase from fiscal 2024.
- Collegium Pharmaceutical, Inc. other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2024 was $41.00K, a 192.86% increase from fiscal 2023.
- Collegium Pharmaceutical, Inc. other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2023 was $14.00K.
| Period end | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 3 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 6 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 9 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 12 month |
|---|---|---|---|---|
| 2026-06-30 | $219.00K 10-Q · filed 2026-08-06 | -$319.00K 10-Q · filed 2026-08-06 | -$292.00K derived: sum of 3 quarters · filed 2026-08-06 | -$337.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$538.00K 10-Q · filed 2026-05-07 | -$511.00K derived: sum of 2 quarters · filed 2026-05-07 | -$556.00K derived: sum of 3 quarters · filed 2026-05-07 | -$460.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $27.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$18.00K derived: sum of 2 quarters · filed 2026-02-26 | $78.00K derived: sum of 3 quarters · filed 2026-08-06 | $264.00K 10-K · filed 2026-02-26 |
| 2025-09-30 | -$45.00K 10-Q · filed 2025-11-06 | $51.00K derived: sum of 2 quarters · filed 2026-08-06 | $237.00K 10-Q · filed 2025-11-06 | -$101.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $96.00K 10-Q · filed 2026-08-06 | $282.00K 10-Q · filed 2026-08-06 | -$56.00K derived: sum of 3 quarters · filed 2026-08-06 | $519.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $186.00K 10-Q · filed 2026-05-07 | -$152.00K derived: sum of 2 quarters · filed 2026-05-07 | $423.00K derived: sum of 3 quarters · filed 2026-05-07 | $365.00K derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$338.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $237.00K derived: sum of 2 quarters · filed 2026-02-26 | $179.00K derived: sum of 3 quarters · filed 2026-02-26 | $41.00K 10-K · filed 2026-02-26 |
| 2024-09-30 | $575.00K 10-Q · filed 2025-11-06 | $517.00K derived: sum of 2 quarters · filed 2025-11-06 | $379.00K 10-Q · filed 2025-11-06 | $445.00K derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | -$58.00K 10-Q · filed 2025-08-07 | -$196.00K 10-Q · filed 2025-08-07 | -$130.00K derived: sum of 3 quarters · filed 2026-02-26 | -$144.00K derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | -$138.00K 10-Q · filed 2025-05-08 | -$72.00K derived: sum of 2 quarters · filed 2026-02-26 | -$86.00K derived: sum of 3 quarters · filed 2026-02-26 | -$124.00K derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $66.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $52.00K derived: sum of 2 quarters · filed 2026-02-26 | $14.00K derived: sum of 3 quarters · filed 2026-02-26 | $14.00K 10-K · filed 2026-02-26 |
| 2023-09-30 | -$14.00K 10-Q · filed 2024-11-07 | -$52.00K derived: sum of 2 quarters · filed 2024-11-07 | -$52.00K 10-Q · filed 2024-11-07 | |
| 2023-06-30 | -$38.00K 10-Q · filed 2024-08-08 | -$38.00K 10-Q · filed 2024-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |